Select a medication above to begin.
iDose TR
travoprost intracameral
Adult Dosing .
Dosage forms: IMPLANT: 75 mcg
elevated IOP
- [1 implant intracamerally x1]
- Info: for patients with open-angle glaucoma or ocular HTN; may re-administer implant x1/yr, see pkg insert for minimum central corneal endothelial cell density; withhold re-administration if ocular or periocular infection, prior implant dislocation, or central corneal endothelial cell loss >10% from baseline
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- ocular infection
- periocular infection
- corneal transplant history
- corneal endothelial cell dystrophy
- corneal endothelial cell transplant history
- caution: iridocorneal angle, narrow
- caution: iridocorneal angle, obstructed
- caution: intraocular inflammation, active
- caution: aphakia
- caution: pseudophakia with torn posterior lens capsule
- caution: macular edema risk
- caution: MRI, concurrent
Drug Interactions .
Overview
travoprost ophthalmic
prostaglandin F2-alpha analog
- alters intraocular pressure
Avoid/Use Alternative
- latanoprost ophthalmic
- travoprost ophthalmic
Monitor/Modify Tx
- bimatoprost ophthalmic
- latanoprostene bunod ophthalmic
- tafluprost ophthalmic
Adverse Reactions .
Serious Reactions
- macular edema
- uveitis
- iritis
- endophthalmitis
- conjunctival hemorrhage
- keratitis
- corneal abrasion
- vitreous detachment
- hypersensitivity reaction
Common Reactions
- IOP incr.
- iritis
- dry eyes
- visual field defect
- eye pain
- ocular hyperemia
- visual acuity decr.
- iris hyperpigmentation
Safety/Monitoring .
Monitoring Parameters
specular microscopy at baseline, then before each re-administration
Pregnancy/Lactation .
Pregnancy
Clinical Summary
may use during pregnancy; no human data available, though risk of fetal harm not expected based on insignificant systemic absorption
Lactation
Clinical Summary
may use while breastfeeding; no human data available, though risk of infant harm and adverse effects on milk production not expected based on insignificant systemic absorption in breastfeeding patients
Pharmacology .
Metabolism: for travoprost: beta-oxidation; CYP450: unknown; Info: minimal systemic absorption
Excretion: for travoprost: urine <2%; Half-life: 45min
Subclass: Glaucoma/Elevated IOP: Prostaglandin Agonists
Mechanism of Action
for travoprost: prodrug converted to travoprost free acid; exact mechanism of action unknown; increases uveoscleral outflow, reducing IOP
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.